CORRECTION



Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use

Katherine A. Lyseng-Williamson¹

Published online: 4 January 2019 © Springer Nature 2019

Correction to:

Drugs & Therapy Perspectives 2018 34(10):457–465 https://doi.org/10.1007/s40267-018-0547-6

The article Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use, written by Katherine A. Lyseng-Williamson, was originally published Online First without open access. After publication in volume 34, issue 10, pages 457–465, Ipsen Pharma requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Ipsen Pharma. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to

the Creative Commons license and indicate if changes were made.

The original article has been corrected.

OpenAccess This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at https://doi.org/10.1007/s40267-018-0547-6.

Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand